EXTON, PA — ProRx Pharma announced it has received a DEA Controlled Substances Registration Certificate, authorizing the company to handle and distribute select controlled substances. The certification expands ProRx’s ability to support healthcare providers with a broader portfolio of compliant medications.
“Earning our DEA Controlled Substances Registration Certificate is a pivotal moment for ProRx,” said Kurt Lunkwitz, chief operating officer at ProRx. “It not only enables us to expand into compounding and distributing Schedule III substances like testosterone, but also demonstrates our commitment to regulatory excellence. This certification strengthens our ability to serve providers with trusted therapies, expand partnerships, and support long-term business growth.”
Schedule III substances, defined under the Controlled Substances Act, include drugs with a currently accepted medical use in the U.S. and a moderate to low potential for physical dependence or high psychological dependence. These substances have a lower abuse potential compared to Schedule I and II drugs but remain tightly regulated.
The DEA certificate signifies that ProRx has met stringent federal requirements related to security, recordkeeping, and accountability. In addition to this new designation, the company also maintains FDA 503B Outsourcing Facility Registration, state pharmacy board licensure, and full compliance with current Good Manufacturing Practices (cGMP).
With the certification, ProRx positions itself to expand its compounding and distribution services while reinforcing its reputation for compliance and safety in pharmaceutical supply.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.